MINNEAPOLIS, Nov. 5, 2024
/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today
announced the release of clinically relevant spatial biology data.
The data was generated using Bio-Techne's Lunaphore branded
end-to-end spatial biology offering, including its complete range
of instruments (COMET) and kits that offer high-value solutions for
the translational research community.
COMET, a best-in-class spatial biology platform, seamlessly
integrates into standard clinical research workflows. Using
off-the-shelf, clinically IHC-validated antibodies, new panels can
be quickly developed and validated. Additionally, COMET enables
high-plex workflow automation, adding unique value to clinical
studies by facilitating robust and timely decision-making in
treatment strategies.
Research conducted in collaboration with Prof. Paolo Ascierto, National Tumor Institute
Fondazione G. Pascale, and leading AI-powered spatial biomarker and
diagnostics company, Nucleai, uncovered potential tumor
microenvironment (TME) features predictive of response to therapy.
In the cohort study of immunotherapy-treated metastatic melanoma
patients, a comprehensive spatial immuno-oncology multiplex
immunofluorescence (mIF) panel was combined for the first time with
advanced AI-powered biomarker analysis. The findings highlight that
the fully- automated workflow and AI tissue analytics can be
applied more broadly in immunotherapy drug development to enhance
the understanding of treatment efficacy, ultimately improving
patient outcomes.
"COMET enables the identification of multiple biomarkers and
spatial interactions between different cell types within the TME,"
said Dr. Ascierto. "Its use together with Nucleai's AI spatial
biomarker platform in predicting therapy response for patients
enrolled in the SECOMBIT1 study, marks the first
application of this innovative technology in a clinical trial,
representing a significant step toward identifying predictive
biomarkers."
"This study demonstrates our shared vision to accelerate
predictive spatial biomarker development and showcases the COMET
platform's unique potential in enabling the design of more
effective immunotherapy strategies in advanced cancers such as
metastatic melanoma, said Dr. Matt
McManus, President of Bio-Techne's Diagnostics & Spatial
Biology Segment. "We're committed to pushing the boundaries of
healthcare by advancing spatial biology in clinical research and
ultimately improve patient outcomes."
Another study conducted in collaboration with Prof. Janis Taube, Johns Hopkins
University School of Medicine, demonstrates the potential of
the novel amplification technique on the COMET platform, allowing
scientists to comprehensively profile the TME, leading the way for
improved insights in clinical research.
At this year's Society for Immunotherapy of Cancer's (SITC)
Annual Meeting novel data sets will be presented, showcasing the
scientific advancements brought by COMET.
To learn more about Lunaphore's poster presentations and
activities at SITC, please visit:
https://lunaphore.com/our-events
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences
company providing innovative tools and bioactive reagents for the
research and clinical diagnostic communities. Bio-Techne products
assist scientific investigations into biological processes and the
nature and progress of specific diseases. They aid in drug
discovery efforts and provide the means for accurate clinical tests
and diagnoses. With hundreds of thousands of products in its
portfolio, Bio-Techne generated approximately $1.2 billion in net sales in fiscal 2024 and has
approximately 3,100 employees worldwide. For more information on
Bio-Techne and its brands, please visit
https://www.bio-techne.com or follow the Company on social
media at: Facebook, LinkedIn, Twitter or YouTube.
About Lunaphore
Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss
company born in 2014 with the vision of enabling spatial biology in
every laboratory. Lunaphore provides solutions based on a
game-changing chip technology that can extract spatial proteomic
and transcriptomic data from tumors and other tissues, transforming
any assay into multiplex spatial biology through a streamlined and
easily integrated process. Lunaphore empowers researchers in
immunology, immuno-oncology, and neuroscience to push the
boundaries of scientific discovery and drug development.
Lunaphore's technology enables the identification of biomarker
"signatures" with clinical relevance to support the development of
diagnostic tools and streamline clinical trials, to ultimately
improve patient outcomes. For further information on Lunaphore and
its products, please visit https://lunaphore.com.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex
platform ensuring scalability and reproducibility without the need
to conjugate primary antibodies. COMET™ provides walk-away
automation, integrating staining, imaging, and image preprocessing
steps to obtain standard hyperplex images. The multiomics
capability of COMET™ enables the simultaneous analysis of both RNA
and protein data within the spatial context of tissues to enhance
the understanding of cellular dynamics and disease processes.
COMET™ generates highly robust and reproducible data with full
tissue preservation, allowing researchers to perform downstream
modalities such as H&E or transcriptomics using the same slide.
Its superior tissue profiling capabilities facilitate the analysis
of 40 different spatial markers in each automated run on a tissue
slide. In contrast to other spatial biology solutions, COMET™ works
with off-the-shelf, label-free primary antibodies, making panel
design much more flexible and faster than any other hyperplex
solution. COMET™ works with regular glass slides from standard
histology workflows; it is validated for human and mouse samples
and is compatible with any other animal sample. The platform can be
used for a wide range of research applications, allowing for a
dramatic improvement in the understanding of disease pathology. To
learn more about the COMET™ platform, please visit:
https://lunaphore.com/products/comet/
Bio-Techne Corporation (NASDAQ: TECH)
David Clair, Vice President, Investor Relations
& Corporate Development
david.clair@bio-techne.com
612-656-4416
For further information on Lunaphore:
Irene Tamayo, Senior Director, Product Strategy
and Marketing
communications@lunaphore.com
1
An international study focusing on the different
sequences of treatment in BRAF-mutated advanced melanoma
patients.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lunaphore-comet-platform-paves-the-way-for-spatial-biology-adoption-in-clinical-research-302295964.html
SOURCE Bio-Techne Corporation
